PROTAGONIST THERAPEUTICS, INC. (NASDAQ:PTGX) Files An 8-K Submission of Matters to a Vote of Security Holders
Item5.07.
|
Submission of Matters to a Vote of Security Holders |
At the Protagonist Therapeutics, Inc. (the Company) 2017 Annual
Meeting of Stockholders (the Annual Meeting) held on May25, 2017,
the stockholders voted on the two proposals listed below. The
proposals are described in detail in the Companys definitive
proxy statement for the Annual Meeting, filed with the Securities
and Exchange Commission on April24, 2017. The results of the
matters voted upon at the meeting were:
Proposal 1 To elect the two ClassI directors
named below to serve until the 2020 Annual Meeting of
Stockholders. Each of the two named nominees was so elected, with
the votes thereon at the Annual Meeting as follows:
| Final Voting Results | ||||||||||||
|
Nominees |
For | Withheld | Broker Non-Votes | |||||||||
|
Julie Papanek |
14,890,655 | 224,529 | 191,602 | |||||||||
|
Dinesh V. Patel, Ph.D. |
14,975,015 | 140,169 | 191,602 |
Proposal 2 To ratify the selection by the Audit
Committee of the Board of Directors of the Company of
PricewaterhouseCoopers LLP as the Companys independent registered
public accounting firm for the fiscal year ending December31,
2017. This proposal was approved by the requisite vote, with the
votes thereon at the Annual Meeting as follows:
| Final Voting Results | ||||||
| For | Against | Abstain | BrokerNon-Votes | |||
| 15,304,894 | 1,892 | |||||
No other matters were submitted for stockholder action.
About PROTAGONIST THERAPEUTICS, INC. (NASDAQ:PTGX)
Protagonist Therapeutics, Inc. is a clinical-stage biopharmaceutical company with a peptide technology platform focused on discovering and developing new chemical entities (NECs) to address significant unmet medical needs. The Company’s product pipeline includes PTG-100, PTG-200 and PTG-300. Its primary focus is on developing oral peptide drugs that target biological pathways also targeted by marketed injectable antibody drugs. PTG-100 is an oral, alpha-4-beta-7 (a4b7) integrin-specific antagonist peptide product candidate, which has completed a Phase I clinical trial in normal healthy volunteers (NHVs). PTG-100 is being developed for treatment of moderate-to-severe ulcerative colitis (UC). PTG-200 is an oral Interleukin-23 receptor (IL-23R) antagonist being developed for moderate-to-severe Crohn’s disease (CD). PTG-200 is in investigational new drug (IND) enabling studies. PTG-300 is an injectable hepcidin mimetic for treatment of iron overload related rare diseases. PROTAGONIST THERAPEUTICS, INC. (NASDAQ:PTGX) Recent Trading Information
PROTAGONIST THERAPEUTICS, INC. (NASDAQ:PTGX) closed its last trading session down -0.51 at 8.59 with 30,716 shares trading hands.